glp 1 agonist drug GLP-1 receptor agonists New GLP-1 Guidelines for Type

In addition, a large number of clinical studies have shown that GLP-/GIP dual agonists can reduce LFC, VAT, and body weight, and have an improvement effect on both NAFLD and NASH [131,132]

GIP is released from the upper small intestine in response to nutrients

It is characterized by insulin resistance, wherein peripheral tissues exhibit a diminished response to insulin, eventually resulting in impaired insulin utilization and relative insulin deficiency [3]

gave 3731 non-diabetics with a BMI of 27 kg/m2 or 30 kg/m2 3 mg of Liraglutide subcutaneously once a day

--- Hashtags: #Cardiology #MedicalEducation #AcuteCoronarySyndrome #STEMI #NSTEMI #UnstableAngina #HeartAttack #ECG #EmergencyMedicine #CriticalCare #InternalMedicine #Healthcare #CardiovascularHealth #ClinicalMedicine #InterventionalCardiology #PatientCare #MedicalProfessionals #DoctorLife #HospitalCare #CardiacRehabilitation #PreventiveCardiology To view or add a comment, sign in 22,293 followers

In the pancreas, GLP-1 binding to its receptor stimulates the proliferation and regeneration of islet -cells and inhibits their apoptosis [10]